The latest price target for VYNE Therapeutics (NASDAQ:VYNE) was reported by HC Wainwright & Co. on February 19, 2025. The analyst firm set a price target for $5.75 expecting VYNE to rise to within 12 months (a possible 134.69% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for VYNE Therapeutics (NASDAQ:VYNE) was provided by HC Wainwright & Co., and VYNE Therapeutics reiterated their buy rating.

There is no last upgrade for VYNE Therapeutics

There is no last downgrade for VYNE Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VYNE Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VYNE Therapeutics was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.

While ratings are subjective and will change, the latest VYNE Therapeutics (VYNE) rating was a reiterated with a price target of $5.75 to $5.75. The current price VYNE Therapeutics (VYNE) is trading at is $2.45, which is out of the analyst’s predicted range.